Oruka Therapeutics, Inc. Common Stock

Day range

$81.98 – $93.42

Open

$81.98

Prev close

$80.15

Volume

1.29M

Market cap

$5.31B

Shares out

66.21M

P/E

—

P/S

—

P/B

4.76

P/FCF

—

ROE

-10.3%

ROA

-10.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive officer appointmentAug 24, 2026

  On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026. Mr. Edwards, age 63, previously served as Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, Inc.

• Annual meeting resultsJun 4, 2026

  On June 2, 2026, Oruka Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-votes as to each such matter.

• Licensing agreementJun 1, 2026

  On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment to IL-23 License Agreement (the "Amendment"), amending the IL-23 License Agreement dated as of December 17, 2024 (the "License Agreement"), by and between the Company and Paragon Therapeutics, Inc. ("Paragon"). The Amendment, among other things, expands the definition of "Field" to encompass all therapeutic, prophylactic, palliative and diagnostic uses, subject to the restriction that the Company will not dose a human patient in a clinical trial of ORKA-001 for inflammatory bowel disease as part of a combination until June 1, 2028 or as a monotherapy until June 1, 2030.

• Public offeringApr 30, 2026

  On April 28, 2026, the Company entered into an Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule A thereto (the "Underwriters"), providing for the offering and sale by the Company of 9,660,000 shares of common stock, par value $0.001 per share (the "Common Stock"), at a price to the public of $72.50 per share (the "Offering").

• Clinical trial resultsApr 27, 2026

  Oruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. ORKA-001 met the primary endpoint of PASI 100 at Week 16, with 63.5% (40/63) of treated patients achieving complete skin clearance compared to 4.8% (1/21) for placebo (p < 0.0001).

Days to cover

6.3

Short interest

7.78M

Avg volume

1.23M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
  positiveGlobeNewswire Inc.· Oct 25, 2026
• These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
  neutralThe Motley Fool· Oct 15, 2026
• Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
  positiveGlobeNewswire Inc.· Sep 23, 2026
• Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
  positiveGlobeNewswire Inc.· Aug 24, 2026
• Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
  neutralThe Motley Fool· Jun 27, 2026